Get the latest news about liver diseases and more
Fatty liver and hepatitis B can coexist and worsen liver damage. Combined treatment helps reduce inflammation, fibrosis, and disease progression.
A study suggests GST-HG141 may become an effective new hepatitis B treatment for patients with incomplete response to current antiviral therapies.
Metabolic syndrome increases the risk of bile duct cancer, especially in patients with fatty liver, where liver disease tends to be more aggressive.
A study shows spironolactone reduces fatty liver risk in patients with hypertension, lowering liver fat accumulation and slowing fibrosis progression.
Autoimmune hepatitis incidence has increased notably in older adults, with higher prevalence and better treatment response, often presenting with milder symptoms.
A study shows that eating fewer than three times a day and fasting over 14 hours increases fatty liver risk due to circadian rhythm disruption.
A study published analyzes the effectiveness of a low-carbohydrate diet in patients with fatty liver disease. Results show weight loss, reduced abdominal circumference, and improvements in liver inflammation and glucose metabolism.
Orforglipron, an oral GLP-1 small molecule, shows significant weight loss results and may become an alternative to injectable drugs like Ozempic or Wegovy.
2 de May de 2020
18 de February de 2024
Up to 30% of patients with cryptogenic hepatitis can be caused by the seronegative hidden infection by hepatitis C virus (HIC).
It is a liver disease of an inflammatory nature and can develop chronically.
Hepatitis A is an acute inflammatory disease of the liver, caused by infection with hepatitis A virus (VAH).